Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii60-iii63. doi: 10.1093/eurheartjsupp/suaf017. eCollection 2025 Mar.
ABSTRACT
Transcatheter edge-to-edge repair (TEER) is currently indicated in symptomatic patients with severe functional mitral regurgitation (MR) who are not eligible for surgery and who have a high likelihood of responding to treatment. This recommendation is based on two randomized trials suggesting that the benefits of TEER may be limited to patients with severe MR, defined by an effective regurgitant orifice area (EROA) ≥0.40 cm2, and a non-excessively remodelled left ventricle. The randomized RESHAPE-HF2 study recently showed that compared to medical therapy alone, treatment with TEER by MitraClip in patients with symptomatic heart failure and less severe functional MR, with lower EROA (mean 0.23 cm2), is associated with a significant reduction in hospitalizations for heart failure, and an improvement in symptoms and quality of life, without a clear benefit on mortality. However, within the cohort of patients with less severe MR enrolled in the RESHAPE-HF2 study, the benefits of MitraClip compared to medical therapy alone seem more significant in selected patients with characteristics associated with a higher risk of heart failure exacerbation, suggesting the importance of careful selection of patients with symptomatic heart failure and MR who could benefit from TEER.
PMID:40248280 | PMC:PMC12001762 | DOI:10.1093/eurheartjsupp/suaf017